Frailty was a significant predictor of severe outcomes and hospitalization characteristics in older adults hospitalized with RSV infection.

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...

The rapid identification of respiratory virus outbreaks is needed to enable rational and effective public health interventions. We developed new quantitative approaches for simultaneous ...

About ENFLONSIA™ (clesrovimab-cfor) ENFLONSIA is Merck’s extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower ...

The RSV vaccine protects against RSV (respiratory syncytial virus), a common seasonal virus that infects the nose, throat, and lungs. While RSV typically causes mild, cold-like symptoms, it can ...

New data for AREXVY, GSK’s RSV vaccine, show potential to help protect a broader group of adults at increased risk for RSV disease ...

GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV seasons ...

Impact of respiratory syncytial virus infection among patients with hematological cancer in the era of post-coronavirus pandemic.. If you have the appropriate software installed, you can download ...

Respiratory syncytial virus (RSV) is a leading cause of severe illness in infants, with no effective treatment. Results of a phase 2 trial suggested that ziresovir may have efficacy in the treatmen ...

Learn about Respiratory Syncytial Virus (RSV), its symptoms, treatment, and prevention. Get expert advice on how to protect vulnerable populations from this viral infection.